Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MicroPort NeuroScientificHKSE:02172 -1.20%93 Current Ratio is 6.01 as of Dec. 2025, which is 14% above its 10-year median of 5.27. GuruFocus rates HKSE:02172 with a GF Score™ of 93/100 and a GF Value™ of HK$13.19 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 853 Medical Devices & Instruments companies, MicroPort NeuroScientific ranks better than 83.94% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. MicroPort NeuroScientific's current ratio for the quarter that ended in Dec. 2025 was 6.01.
MicroPort NeuroScientific has a current ratio of 6.01. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for MicroPort NeuroScientific's Current Ratio or its related term are showing as below:
HKSE:02172'
s Current Ratio Range Over the Past 10 Years
Min: 0.8 Med: 5.27 Max: 6.01
Current: 6.01
During the past 7 years, MicroPort NeuroScientific's highest Current Ratio was 6.01. The lowest was 0.80. And the median was 5.27.
HKSE:02172's Current Ratio is ranked better than 83.94% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 2.49
vs HKSE:02172: 6.01
MicroPort NeuroScientific (HKSE:02172) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
MicroPort NeuroScientific Current Ratio Related Terms
MicroPort NeuroScientific Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02172 vs ABT, SYK, MDT: Current Ratio Comparison
For the Medical Devices subindustry, MicroPort NeuroScientific's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MicroPort NeuroScientific Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MicroPort NeuroScientific's Current Ratio distribution charts can be found below:
* The bar in red indicates where MicroPort NeuroScientific's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MicroPort NeuroScientific (HKSE:02172) has a Current Ratio of 6.01 as of Dec. 2025. This is 14% above median its historical median of 5.27. Over the past decade, MicroPort NeuroScientific's Current Ratio has ranged from 0.80 to 6.01. According to the industry distribution chart, MicroPort NeuroScientific ranks #137 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 16.1%.
Is MicroPort NeuroScientific's Current Ratio too high?
MicroPort NeuroScientific's current Current Ratio of 6.01 is 14% above median its 10-year median of 5.27. Over the past 10 years, this metric has ranged from a low of 0.80 to a high of 6.01. The Medical Devices & Instruments industry median Current Ratio is 2.49. MicroPort NeuroScientific's value of 6.01 is 141.4% above this industry median. Based on the distribution chart, MicroPort NeuroScientific ranks #137 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MicroPort NeuroScientific has a GF Score™ of 93/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MicroPort NeuroScientific's Current Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MicroPort NeuroScientific ranks #137 out of 853 companies for Current Ratio. This places MicroPort NeuroScientific in the top 16% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.49. MicroPort NeuroScientific's value of 6.01 is 141.4% above this benchmark. Historically, MicroPort NeuroScientific's own Current Ratio has ranged from 0.80 to 6.01 over the past decade. While the company's 10-year median is 5.27 vs. the industry median of 2.49, MicroPort NeuroScientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MicroPort NeuroScientific's current Current Ratio of 6.01 is 141.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MicroPort NeuroScientific's current Current Ratio is 6.01, which is 14% above median its own 10-year median of 5.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MicroPort NeuroScientific stock overvalued right now?
Based on GuruFocus' analysis, MicroPort NeuroScientific (HKSE:02172) is currently considered Possible Value Trap. The stock's GF Value™ is HK$13.19, compared to a current price of HK$9.02 — trading 31.6% below its estimated fair value. The current Current Ratio is 6.01, which is 14% above median its 10-year median of 5.27 and 141.4% above the Medical Devices & Instruments industry median of 2.49. MicroPort NeuroScientific's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For MicroPort NeuroScientific (HKSE:02172), the current Current Ratio is 6.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MicroPort NeuroScientific (HKSE:02172) Overvalued in 2026?
Based on GuruFocus' analysis, MicroPort NeuroScientific stock appears to be undervalued.
The current stock price of HK$9.02 is trading 31.6% below its estimated GF Value™ of HK$13.19.
GuruFocus considers MicroPort NeuroScientific to be Possible Value Trap.
Key valuation signals for HKSE:02172:
Current Ratio: 6.01 (14% above median its 10-year median of 5.27)
GF Value™: HK$13.19 vs. price of HK$9.02 (31.6% below fair value)
Industry Position: 141.4% above the Medical Devices & Instruments median (#137 of 853)
No single metric tells the full story. See the HKSE:02172 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MicroPort NeuroScientific Corp is in the neuro-interventional medical device industry, dedicated to providing solutions for physicians and patients. The company boasts a comprehensive portfolio of approved therapeutic products covering all of three main areas of neurovascular disease, namely hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke. The company generates almost all of its revenue from the sale of medical devices. Geographically, the company generates the majority of its revenue from the PRC region, and also has operations in Israel.
93GF Score
Get the complete analysis for HKSE:02172
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02172 has been successfully added to your 
